EUVIMEDEUVIMED entdecken
VergleichsstudieLeserbrief

Time From Approval to Reimbursement of New Drugs: A Comparative Analysis Between the United States, England, Germany, France, and Switzerland (2011–2022)

Camille E G Glaus, Miquel Serra-Burriel iD, Stacie B Dusetzina iD, Kerstin N Vokinger

Annals of Internal Medicine · 2024-10 · 177 (10) · 1442-1444

DOI: 10.7326/annals-24-00614 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Annals of Internal Medicine, 2024-10. Verfasst von Camille E G Glaus und 3 weiteren Autor:innen. Beteiligte Einrichtung: Academic Chair for Regulation in Law, Medicine, and Technology, Faculty of Law and Faculty of Medicine, University of Zurich, Zurich, Switzerland. Hauptthemen laut MEDLINE: Drug Approval. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 2 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

ZORA (Zurich Open Repository and Archive) provides open and worldwide access to the research and scholarly output of the University of Zurich, Switzerland. A focus is on qualified scientific publications. ZORA is operated by the University Library together with the Central IT of the University of Zurich.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug ApprovalHumansUnited StatesSwitzerlandFranceTime FactorsGermanyEngland

Autor:innen und Institutionen

  • Academic Chair for Regulation in Law, Medicine, and Technology, Faculty of Law and Faculty of Medicine, University of Zurich, Zurich, Switzerland.
  • Academic Chair for Regulation in Law, Medicine, and Technology, Faculty of Law and Faculty of Medicine, and Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland.
  • Professor of Health Policy and Ingram Professor of Cancer Research, Vanderbilt University School of Medicine, Department of Health Policy, and Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.
  • Professor of Law and Medicine, Academic Chair for Regulation in Law, Medicine, and Technology, Faculty of Law and Faculty of Medicine, University of Zurich, Zurich, Switzerland.

ORCID-Profile: Miquel Serra-Burriel, Stacie B Dusetzina

Zitieren

APA

Glaus, C. E. G., Serra-Burriel, M., Dusetzina, S. B., & Vokinger, K. N. (2024). Time From Approval to Reimbursement of New Drugs: A Comparative Analysis Between the United States, England, Germany, France, and Switzerland (2011–2022). Annals of Internal Medicine, 177(10), 1442-1444. https://doi.org/10.7326/annals-24-00614

Vancouver

Glaus CEG, Serra-Burriel M, Dusetzina SB, Vokinger KN. Time From Approval to Reimbursement of New Drugs: A Comparative Analysis Between the United States, England, Germany, France, and Switzerland (2011–2022). Annals of Internal Medicine. 2024;177(10):1442-1444. doi:10.7326/annals-24-00614

BibTeX
@article{Glaus2024,
  author = {Glaus, Camille E G and Serra-Burriel, Miquel and Dusetzina, Stacie B and Vokinger, Kerstin N},
  title = {Time From Approval to Reimbursement of New Drugs: A Comparative Analysis Between the United States, England, Germany, France, and Switzerland (2011–2022)},
  journal = {Annals of Internal Medicine},
  year = {2024},
  volume = {177},
  number = {10},
  pages = {1442--1444},
  doi = {10.7326/annals-24-00614}
}
Kostenlos starten →